GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Coloplast AS (OCSE:COLO B) » Definitions » EV-to-FCF

Coloplast AS (OCSE:COLO B) EV-to-FCF : 143.60 (As of Jan. 18, 2025)


View and export this data going back to 1993. Start your Free Trial

What is Coloplast AS EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Coloplast AS's Enterprise Value is kr203,912 Mil. Coloplast AS's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was kr1,420 Mil. Therefore, Coloplast AS's EV-to-FCF for today is 143.60.

The historical rank and industry rank for Coloplast AS's EV-to-FCF or its related term are showing as below:

OCSE:COLO B' s EV-to-FCF Range Over the Past 10 Years
Min: 32.08   Med: 50.31   Max: 218.54
Current: 143.6

During the past 13 years, the highest EV-to-FCF of Coloplast AS was 218.54. The lowest was 32.08. And the median was 50.31.

OCSE:COLO B's EV-to-FCF is ranked worse than
91.62% of 370 companies
in the Medical Devices & Instruments industry
Industry Median: 27.565 vs OCSE:COLO B: 143.60

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-01-18), Coloplast AS's stock price is kr808.00. Coloplast AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was kr22.460. Therefore, Coloplast AS's PE Ratio (TTM) for today is 35.98.


Coloplast AS EV-to-FCF Historical Data

The historical data trend for Coloplast AS's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coloplast AS EV-to-FCF Chart

Coloplast AS Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 56.06 65.07 46.11 62.52 154.23

Coloplast AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.52 45.34 221.70 161.39 154.23

Competitive Comparison of Coloplast AS's EV-to-FCF

For the Medical Instruments & Supplies subindustry, Coloplast AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coloplast AS's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Coloplast AS's EV-to-FCF falls into.



Coloplast AS EV-to-FCF Calculation

Coloplast AS's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=203912.048/1420
=143.60

Coloplast AS's current Enterprise Value is kr203,912 Mil.
Coloplast AS's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1,420 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Coloplast AS  (OCSE:COLO B) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Coloplast AS's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=808.00/22.460
=35.98

Coloplast AS's share price for today is kr808.00.
Coloplast AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr22.460.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Coloplast AS EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Coloplast AS's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Coloplast AS Business Description

Traded in Other Exchanges
Address
Holtedam 1-3, Humlebaek, DNK, DK-3050
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.

Coloplast AS Headlines

No Headlines